FDCDDQ
NRIX icon

Federation des caisses Desjardins du Quebec’s Nurix Therapeutics NRIX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.7K Sell
2,090
-500
-19% -$8.52K ﹤0.01% 1928
2026
Q1 		$40.1K Buy
2,590
+1,000
+63% +$16.6K ﹤0.01% 1923
2025
Q4 		$30.2K Hold
1,590
– – ﹤0.01% 1952
2025
Q3 		$14.7K Buy
1,590
+800
+101% +$8.31K ﹤0.01% 2123
2025
Q2 		$9K Hold
790
– – ﹤0.01% 2071
2025
Q1 		$9.38K Buy
790
+500
+172% +$8.36K ﹤0.01% 1982
2024
Q4 		$5.46K Sell
290
-700
-71% -$16K ﹤0.01% 2057
2024
Q3 		$22.2K Sell
990
-700
-41% -$15.9K ﹤0.01% 1634
2024
Q2 		$35.3K Buy
1,690
+490
+41% +$7.63K ﹤0.01% 1468
2024
Q1 		$17.6K Hold
1,200
– – ﹤0.01% 1675
2023
Q4 		$12.4K Hold
1,200
– – ﹤0.01% 1702
2023
Q3 		$9.43K Hold
1,200
– – ﹤0.01% 1773
2023
Q2 		$12K Buy
1,200
+700
+140% +$7.14K ﹤0.01% 1703
2023
Q1 		$4.44K Buy
+500
New +$5.21K ﹤0.01% 1939

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federation des caisses Desjardins du Quebec's NRIX Position: Q2 2026 in Review

Federation des caisses Desjardins du Quebec reduced its Nurix Therapeutics (NRIX) stake by 19% in Q2 2026, selling an estimated $8.52K and leaving 2,090 shares worth $50.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1928.

Federation des caisses Desjardins du Quebec first reported a position in NRIX in Q1 2023 and has held it in 14 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Federation des caisses Desjardins du Quebec held 2,090 shares of Nurix Therapeutics worth $50.7K as of Q2 2026.
  • Federation des caisses Desjardins du Quebec sold 500 Nurix Therapeutics shares in Q2 2026, an estimated $8.52K.
  • Nurix Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #1928 holding.
  • Federation des caisses Desjardins du Quebec first reported a position in Nurix Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.